Regeneron and Novartis on Innovating to Accommodate Growing Pipelines

In this session recorded at DPHARM 2022, Bari Kowal, SVP & Head, Development Operations and Portfolio Management, Regeneron, moderates a panel discussion on:

• Examining how modernizations like the implementation of AI/ML, RWE, DE&I, DCTs impact the need for more flexibility clinical trial design
• Building protocols in tandem with study design and re-envisioning methods to execute trials

Panelists include:

• Henry Wei, MD, Head of Development Innovation, Regeneron
• Rinol Alaj, MBA, Senior Director, Head of Clinical Outcomes Assessment & Patient Innovation, Regeneron
• Bill Illis, Global Head, Collaboration and Technology Strategy, Clinical Development & Analytics, Novartis